ArticleVeterinary research communications2016
Immunoprotection of recombinant Eg.P29 against Echinococcus granulosus in sheep.
Article in Veterinary research communications, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 27 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
27 citing papers in PubMed, 45 citations in OpenAlex.
- Effects of recombinantFrontiers in cellular and infection microbiology · 2026Article
- Article
- miR-378a-5p targeting BRAF regulates CD4Frontiers in immunology · 2025Article
- Screening and identification of protein 29 ofFrontiers in cellular and infection microbiology · 2025Article
- PreliminaryRecent advances in inflammation & allergy drug discovery · 2025Article
- Enhancing the structural stability of P29-targeted monoclonal antibodies via β-hydroxybutyrylation modification improves their therapeutic performance in alveolar echinococcosis.Frontiers in cellular and infection microbiology · 2025Article
- Designing and Evaluation of a Plasmid Encoding Immunogenic Epitopes FromJournal of parasitology research · 2025Article
- Designing multi-epitope vaccines against Echinococcus granulosus: an in-silico study using immuno-informatics.BMC molecular and cell biology · 2024Article
- Enhancing the therapeutic potential of P29 protein-targeted monoclonal antibodies in the management of alveolar echinococcosis through CDC-mediated mechanisms.PLoS pathogens · 2024Article
- Immunoprotective effect and mechanism of rEg.P29 against CD4Acta biochimica et biophysica Sinica · 2024Article
- Optimizing sheep B-cell epitopes inFrontiers in immunology · 2024Article
- Changes in intestinal flora of mice induced by rEg.P29 epitope peptide vaccines.Immunity, inflammation and disease · 2023Article
- Immunogenicity of peptide-based vaccine composed of epitopes from Echinococcus granulosus rEg.P29.FASEB journal : official publication of the Federation of American Societies for Experimental Biology · 2023Article
- Article
- Recombinant antigen P29 ofFrontiers in immunology · 2023Article
- Clinical characteristics and antibodies against Echinococcus granulosus recombinant antigen P29 in patients with cystic echinococcosis in China.BMC infectious diseases · 2022Article
- Expression and production of protoscolex recombinant P29 protein and its serological evaluation for diagnosis of human hydatidosis.Journal of parasitic diseases : official organ of the Indian Society for Parasitology · 2022Article
- Identification of B-cell dominant epitopes in the recombinant protein P29 from Echinococcus granulosus.Immunity, inflammation and disease · 2022Article
- Identification of a dominant murine T-cell epitope in recombinant protein P29 from Echinococcus granulosusActa biochimica et biophysica Sinica · 2022Article
- The RecombinantFrontiers in immunology · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveThis study aims to investigate the immunoprotection of recombinant Eg.P29 (rEg.P29) vaccine and analyze the underlying mechanism in sheep.
methodsThree groups of male sheep were immunized subcutaneously with rEg.P29 and PBS, Freund's complete adjuvant as controls, respectively. After prime-boost vaccination, the sheep were challenged with encapsulated Echinococcus granulosus eggs. The percentage of protection in sheep was determined 36 weeks after the infection. Humoral immune response was analyzed for specific IgG, IgG1, IgG2, IgM and IgE levels. Moreover, cytokines including interferon (IFN)-γ, interleukin (IL)-2, IL-4,and IL-10 were also evaluated.
resultsImmunization with rEg.P29 induced protective immune responses up to 94.5 %, compared with immunoadjuvant group. The levels of specific IgG, IgG1, IgG2, and IgE as well as IFN-γ, IL-2, and IL-4 significantly increased after two immunizations (P < 0.05); however, the levels of IgM and IL-10 did not show difference.
conclusionrEg.P29 showed Immunoprotection and induced Th1 and Th2 immune responses; hence, rEg.P29 is a potential vaccine for E. granulosus infection.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.